Results 231 to 240 of about 3,900,144 (339)

The role of mental health problems and common psychotropic drug treatments in accidental injury at work: a case–control study

Occupational and Environmental Medicine, 2014
K. Palmer, Stefania D ’ Angelo, Clare Harris, C. Linaker, D. Coggon   +4 more
semanticscholar   +1 more source

A feasibility study of two variants of a blended functional remediation programme for euthymic patients with bipolar I disorder

British Journal of Clinical Psychology, EarlyView.
Abstract Background Bipolar disorder (BD) is associated with reduced psychosocial functioning, partly due to cognitive impairments. Functional remediation (FR), aimed at ameliorating daily functioning, is based on psychoeducation and strategies to cope with cognitive problems.
Susan Zyto, Ralph W. Kupka, Annet Nugter, Peter F. J. Schulte, Marieke van Eijkelen, Eline Regeer, Sigfried Schouws   +6 more
wiley   +1 more source

Predictors of depressive symptoms and depression in women with previous pregnancy loss

British Journal of Clinical Psychology, EarlyView.
Abstract Objectives Depressive symptoms are common in females after pregnancy loss. However, research on risk factors for developing a clinical depressive episode remains limited and with inconsistent findings. This study examined the association of demographic variables (like age), pregnancy‐related factors (like number of miscarriages or stillbirths),
Sarah M. Quaatz, Roland Mergl, Franziska Bichlmayer, Helena Hoffmann, Kathryn Eichhorn, Antje‐Kathrin Allgaier, Svenja Hoffmann   +6 more
wiley   +1 more source

Therapy after therapy: Entry rates into subsequent psychological treatment among patients receiving therapist‐guided internet‐delivered or face‐to‐face psychotherapy

British Journal of Clinical Psychology, EarlyView.
Abstract Objectives Despite numerous psychotherapy trials, knowledge on service‐system efficiency in terms of return to treatment is limited, especially regarding internet‐delivered cognitive behavioural therapy (iCBT). We estimated the hazard ratio (HR) of subsequent psychological treatment over several years following the initial psychological ...
A. Plattonen, S. Mylläri, S. E. Saarni, T. Rosenström   +3 more
wiley   +1 more source

The Recruitment and Retention of Individuals With Intellectual Disability in Randomized Controlled Trials: A Scoping Review

British Journal of Learning Disabilities, EarlyView.
ABSTRACT Background People with intellectual disabilities face significant health disparities and often encounter barriers in accessing healthcare services. Although research supports the need for reasonable adjustments to improve healthcare access for this population, implementation in acute healthcare settings remains limited.
Owen Doody, Louise Murphy, Ruth Ryan, Rosemary Lyons, Wenyi Tang, Lorna Bourke   +5 more
wiley   +1 more source

Integrative Care for Challenging Behaviors in People with Intellectual Disabilities to Reduce Challenging Behaviors and Inappropriate Psychotropic Drug Prescribing Compared with Care as Usual: A Cluster-Randomized Trial. [PDF]

Int J Environ Res Public Health
de Kuijper G, Jonker J, Kouwer K, Hoekstra PJ, de Bildt A.   +4 more
europepmc   +1 more source

Psychotropic drugs. [PDF]

BMJ, 1968
openaire   +2 more sources

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source